662 related articles for article (PubMed ID: 25470746)
1. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
Schürmann D; Sobotha C; Gilmartin J; Robberechts M; De Lepeleire I; Yee KL; Guo Y; Liu R; Wagner F; Wagner JA; Butterton JR; Anderson MS
AIDS; 2016 Jan; 30(1):57-63. PubMed ID: 26372481
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
Matthews RP; Jackson Rudd D; Fillgrove KL; Zhang S; Tomek C; Stoch SA; Iwamoto M
Clin Drug Investig; 2021 Jul; 41(7):629-638. PubMed ID: 34151413
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M
Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
8. Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
Ankrom W; Yee KL; Sanchez RI; Adedoyin A; Fan L; Marbury T; Preston RA; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891610
[TBL] [Abstract][Full Text] [Related]
9. A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Vaynshteyn K; Deschamps K; Martell M; Jordan HR; Iwamoto M
J Clin Pharmacol; 2019 Aug; 59(8):1093-1098. PubMed ID: 30817001
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Sanchez RI; Fillgrove KL; Yee KL; Liang Y; Lu B; Tatavarti A; Liu R; Anderson MS; Behm MO; Fan L; Li Y; Butterton JR; Iwamoto M; Khalilieh SG
Xenobiotica; 2019 Apr; 49(4):422-432. PubMed ID: 29557716
[TBL] [Abstract][Full Text] [Related]
11. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.
Sanchez RI; Yee KL; Fan L; Cislak D; Martell M; Jordan HR; Iwamoto M; Khalilieh S
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):107-114. PubMed ID: 30973682
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
[TBL] [Abstract][Full Text] [Related]
17. Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Anderson MS; Sura M; Laethem T; Rasmussen S; van Bortel L; van Lancker G; Iwamoto M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30783000
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Yee KL; Cabalu TD; Kuo Y; Fillgrove KL; Liu Y; Triantafyllou I; McClain S; Dreyer D; Wenning L; Stoch SA; Iwamoto M; Sanchez RI; Khalilieh SG
J Clin Pharmacol; 2021 Mar; 61(3):394-405. PubMed ID: 32989795
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Drug Interactions of Doravirine.
Wilby KJ; Eissa NA
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):637-644. PubMed ID: 30047107
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
